Significados de cytoreductive surgery en inglés

Favorable survival rates may be associated with octretide treatment and cytoreductive surgery.

Optimal secondary cytoreductive surgery was possible in 11 patients in PR after chemotherapy.

Following cytoreductive surgery of the mass, palliative radiation therapy was administered.

The impact of secondary cytoreductive surgery on survival requires more investigation.

Previously, an initial laparotomy had been performed for staging and maximum cytoreductive surgery.

This study evaluates cytoreductive surgery and IPHC with peritoneal carcinomatosis from gastric carcinoma.

Results: 51 patients with ovarian carcinosarcoma were identified and all underwent primary cytoreductive surgery.

All patients underwent cytoreductive surgery followed by conventional platinum-based chemotherapy.

The effect of HIPEC remains undetermined in patients who are candidates for primary cytoreductive surgery.

The timing and impact of cytoreductive surgery on the success of immunotherapy require further study.

A median survival of 95 months was observed among patients who did not undergo cytoreductive surgery.

These findings suggest that adjuvant active specific immunotherapy should be considered after cytoreductive surgery for advanced melanoma.

Age, performance status, stage of disease, and extent of cytoreductive surgery are important independent prognostic factors for survival.

Multimodality treatment of metastatic renal cell carcinoma with biological response modifiers and cytoreductive surgery has produced durable responses.

For this inherently high-risk population, this information is critical when counseling patients about peri-operative risks in primary cytoreductive surgery.

Methods: Sixty-four paraffin-embedded tissue specimens were obtained from patients with ovarian cancer who received cytoreductive surgery and combination chemotherapy.